Immune booster trial offers new hope for kids with stubborn nerve cancer

NCT ID NCT07375563

Recruiting now Disease control Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology Source: ClinicalTrials.gov ↗

First seen Feb 01, 2026 · Last updated May 20, 2026 · Updated 13 times

Summary

This Phase 3 trial tests a powerful mix of chemotherapy, immunotherapy, and the child's own immune cells (natural killer cells) for children aged 1.5 to 18 with high-risk neuroblastoma that did not respond to initial treatment or has returned. The goal is to shrink tumors and improve survival by helping the immune system fight the cancer more effectively. Only 5 children will take part in this early-stage study.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GANGLIONEUROBLASTOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

National medical research center of pediatric haematology, oncology and immulogy named after Dmytriy Rogachyov, Moscow, 117198
RECRUITING

Moscow, 117198, Russia

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

GANGLIONEUROBLASTOMA NEUROBLASTOMA (NB) NEUROBLASTOMA (NB)